ASSET PURCHASE AGREEMENT by and between Denovo Biopharma LLC and Tocagen Inc. Dated as of April 17, 2020Asset Purchase Agreement • May 12th, 2020 • Tocagen Inc • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (as may be amended from time to time, this “Agreement”) is made and entered into as of April 17, 2020, by and between DENOVO BIOPHARMA LLC, a Delaware limited liability company (“Purchaser”) and TOCAGEN INC., a Delaware corporation (“Seller”). Certain capitalized terms used in this Agreement are defined in Exhibit A. Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
WAIVER AND AMENDMENTWaiver and Amendment • May 12th, 2020 • Tocagen Inc • Pharmaceutical preparations • Delaware
This Waiver and Amendment (this “Waiver and Amendment”) is entered into on May 11, 2020 by and among Tocagen Inc., a Delaware corporation (“Parent”), Telluride Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Forte Biosciences, Inc., a Delaware corporation (the “Company”). Each of Parent, Merger Sub and the Company is a “Party,” and collectively, the “Parties.” Capitalized terms used but not otherwise defined in this Waiver and Amendment will have the same meanings ascribed to such terms in the Merger Agreement (as defined below).
ASSET PURCHASE AGREEMENT by and between Abintus Bio, Inc. and Tocagen Inc. Dated as of April 9, 2020Asset Purchase Agreement • May 12th, 2020 • Tocagen Inc • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (as may be amended from time to time, this “Agreement”) is made and entered into as of April 9, 2020, by and between ABINTUS BIO, INC., a Delaware corporation (“Purchaser”) and TOCAGEN INC., a Delaware corporation (“Seller”). Certain capitalized terms used in this Agreement are defined in Exhibit A. Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
